Saudi Central Bank Has $7.60 Million Stock Position in Stryker Corporation $SYK

Key Points

• Saudi Central Bank increased its Stryker stake by 89.9% in the second quarter, acquiring 11,424 additional shares and bringing its holdings to 24,128 shares valued at approximately $7.6 million. Institutional investors and hedge funds collectively own 77.09% of SYK.
• Stryker insiders sold 351,267 shares worth roughly $118.2 million over the past 90 days, including a director’s $100.8 million sale of 300,000 shares.
• Analysts maintain a generally positive outlook, with the stock rated “Moderate Buy” and an average price target of $386.28. Stryker recently exceeded quarterly earnings expectations, reporting $3.69 in EPS and $6.59 billion in revenue, while maintaining a $0.88 quarterly dividend.

Saudi Central Bank boosted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 89.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,128 shares of the medical technology company's stock after acquiring an additional 11,424 shares during the period. Saudi Central Bank's holdings in Stryker were worth $7,596,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SYK. Brighton Jones LLC raised its stake in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new stake in Stryker during the second quarter valued at $205,000. Marshall Wace LLP grew its holdings in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company's stock worth $2,255,000 after acquiring an additional 77,831 shares during the period. Nebula Research & Development LLC acquired a new stake in Stryker during the 2nd quarter worth about $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker in the 2nd quarter worth about $253,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Transactions at Stryker

In related news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda Stryker sold 300,000 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director owned 2,301,375 shares of the company's stock, valued at $773,031,862.50. This trade represents a 11.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last ninety days. 4.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SYK. Argus set a $370.00 price objective on Stryker in a research note on Thursday, July 9th. UBS Group initiated coverage on Stryker in a research note on Tuesday, July 28th. They set a "buy" rating and a $400.00 target price for the company. JPMorgan Chase & Co. lowered their target price on Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a report on Friday, July 31st. Citigroup restated a "buy" rating on shares of Stryker in a report on Thursday, August 13th. Finally, Citizens Jmp reduced their price objective on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $386.28.

Stryker Price Performance

SYK stock opened at $302.92 on Friday. The stock has a market capitalization of $116.19 billion, a PE ratio of 31.39, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. The company's 50-day moving average is $328.84 and its 200-day moving average is $329.73. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.37.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the company posted $3.13 EPS. The firm's revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker's payout ratio is currently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source